drugset / Trial / NCT00924443

A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable

NCT00924443

Phase 2 Completed 69 enrolled Genzyme, a Sanofi Company Bioenvision · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if treatment of older patients indicated with untreated Acute Myeloid Leukemia (AML) who are not considered to be suitable for intensive chemotherapy, can effectively be treated with Clofarabine.

Timeline

Start
2004-06
Primary completion
2006-06
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 20 mg/m2 Intravenous